Pentoxifilina Genfar

Quick links

Choose a section

Quick links to important sections

Advertisements
Advertisements

Overview of Pentoxifilina Genfar

Property Description
Active ingredient Pentoxifylline (or Oxpentifylline)
Form Extended-Release Oral Tablet
Pharmacological class Hemorrheologic Agent
Common use Improving blood flow and circulation
Origin Synthetic Methylxanthine Derivative

What Type of Medicine is Pentoxifilina Genfar?

Pentoxifilina Genfar is a prescription medication whose sole active component is the substance Pentoxifylline, which may also be referred to by the synonym Oxpentifylline. It is specifically manufactured and marketed by Genfar, positioning it as a widely recognized generic form of the drug in various regions. Pentoxifylline is chemically classified as a synthetic methylxanthine derivative, and its primary designation is that of a hemorrheologic agent, a class of medicines designed to modulate the flow properties of blood and alter blood dynamics.


Composition and Pharmaceutical Form

The medication is a single-ingredient product, containing only Pentoxifylline and the necessary pharmaceutical excipients. Pentoxifilina Genfar is manufactured for oral administration and is typically presented as an extended-release tablet (tableta de liberación prolongada). This extended-release characteristic is critical to the product's identity, as it ensures the active substance is delivered slowly and consistently into the bloodstream over time. This steady release helps to maintain a continuous therapeutic effect.


What is the General Purpose of Pentoxifylline?

The general purpose of Pentoxifylline is centered on enhancing microcirculation and improving overall blood flow. It achieves this through a specific, combined physiological action that reduces blood viscosity (making the blood less thick) while concurrently increasing the flexibility of red blood cells. This effect on the physical characteristics of blood is designed to help the blood pass more easily and efficiently through narrow or compromised vessels, which is the overarching general benefit provided by this medication. This action is used in contexts requiring support for improved circulation, such as addressing limited blood flow in the lower limbs.

Regulatory References

  1. StatPearls - NCBI Bookshelf
Advertisements

What side effects are possible with Pentoxifilina Genfar?

Possible Side Effects and Safety Information

The safety profile of Pentoxifilina Genfar (Pentoxifylline) is defined by official regulatory documents, which classify potential adverse reactions primarily based on frequency and the body system affected. The most frequently reported reactions in clinical data typically involve the Gastrointestinal and Nervous Systems, including nausea, vomiting, dizziness, and headache.


System-Organ Classifications and Serious Reactions

The adverse reactions are categorized across several systems, including Vascular/Cardiac, Blood/Lymphatic, Immune System, and Skin disorders. Though generally less common, the official safety profile includes reports of more significant events, such as Haemorrhage (bleeding), Thrombocytopenia (low platelet count), and serious immune responses like Anaphylactic Reactions or Aseptic Meningitis.


Population-Specific Safety Considerations

Explicit safety notes exist for specific patient populations. The medication is generally not recommended for individuals with severe hepatic impairment or severe renal impairment due to altered drug metabolism and excretion. Older adults may require closer monitoring due to a higher frequency of age-related organ function decline. Pentoxifylline is classified as Pregnancy Category C.


Safety Constraints and Contraindications

Official prescribing information establishes strict constraints for its use. The medication is contraindicated in patients with known hypersensitivity to pentoxifylline or other Xanthine derivatives (like caffeine or theophylline). It must also not be used in individuals with recent cerebral or retinal haemorrhage, a history of peptic ulcers, or those suffering from severe cardiac arrhythmias.

Advertisements

Overdose and Emergency Response

Overdose and when to seek help

The following information details the officially documented signs of overdose and required emergency actions for Pentoxifilina Genfar (Pentoxifylline), strictly based on governmental regulatory sources.


Documented Overdose Manifestations

Official regulatory documents describe a variety of clinical manifestations following an overdose, primarily affecting the central nervous and cardiovascular systems. These signs may include drowsiness, agitation, seizure (convulsions), fever, flushing, and faintness. Gastrointestinal distress is also documented, including nausea, vomiting, and diarrhea. Severe, potentially life-threatening outcomes include significant hypotension (low blood pressure), cardiac arrhythmia (irregular or fast heartbeat), and loss of consciousness.

When to Seek Urgent Medical Help

The regulatory mandate is to seek emergency medical attention immediately upon any suspicion of overdose or if severe symptoms such as seizures or severe hypotension occur. Individuals should also contact a Poison Help line or Poison Control Center at once.

Overdose Management and Monitoring

Management of a Pentoxifylline overdose is symptomatic and supportive, as no specific antidote is known according to regulatory labeling. Treatment requires medical professionals to give particular attention to supporting the cardiovascular system within a monitored setting. Patients with impaired renal function and elderly patients may be at greater risk of toxic reactions due to potential drug metabolite accumulation.

Advertisements

Therapeutic Uses of Pentoxifilina Genfar

Quick Facts

  • Condition Managed: Intermittent Claudication
  • Primary Effect: Helps manage symptoms of leg pain due to chronic arterial disease
  • Therapeutic Goal: May improve walking ability and reduce associated discomfort

What Pentoxifilina Genfar Treats: Main Uses and Benefits

Pentoxifilina Genfar is a prescription medication utilized in the management of a condition known as intermittent claudication. This condition is characterized by pain, cramping, or discomfort in the legs that occurs during physical activity, such as walking, and is linked to chronic occlusive arterial disease in the limbs. The core therapeutic domain of this drug is to address the symptoms experienced by affected individuals.

Through its pharmacological actions, this medication works to support the flow properties of blood. This effect may contribute to improving blood circulation, particularly in the microcirculation of the affected extremities. The overall clinical benefit is intended to help reduce the frequency and severity of the associated discomfort, which may improve functional capacity and increase the distance a patient can walk without experiencing pain. It is an element of a comprehensive treatment plan and is not intended to replace definitive procedures like surgical intervention.

Advertisements

Eligibility and Restrictions for Use

Who Can and Cannot Use Pentoxifilina Genfar?

This section summarizes the patient eligibility and non-eligibility rules for Pentoxifilina Genfar (Pentoxifylline), based strictly on official governmental regulatory documentation.


Contraindications and Non-Eligibility

Pentoxifilina Genfar must not be used (is contraindicated) in patients with the following conditions:

  • Known hypersensitivity or intolerance to Pentoxifylline or any other methylxanthine derivatives (e.g., caffeine, theophylline).
  • Recent cerebral hemorrhage or extensive retinal hemorrhage.
  • Active peptic ulcer or acute myocardial infarction (as specified in some official labels).

Population and Organ Function Restrictions

Population Group Regulatory Status
Pediatric Population (under 18 years) Use Not Established. Safety and efficacy data are not sufficient in this age group, and use is generally not recommended.
Pregnancy and Lactation Not Recommended. Use during pregnancy (Category C) is restricted; the drug is excreted into human milk.
Severe Renal/Hepatic Impairment Conditional Use. Requires caution and mandated dose reduction when organ function is severely compromised.
High Bleeding Risk Conditional Use. Requires close monitoring due to the risk of exacerbating existing bleeding conditions or hemorrhagic tendencies.
Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Pentoxifylline (the active ingredient in Pentoxifilina Genfar) identifies specific combination restrictions and interaction types based on pharmacokinetic and pharmacodynamic profiles.

Classification Constraint / Affected Substance
Contraindicated Combinations Co-administration with Riociguat is contraindicated due to the potential for severe hypotension. Use is also prohibited in individuals intolerant to other Methylxanthine derivatives (e.g., Theophylline).
Pharmacokinetic Interactions Ciprofloxacin, Fluvoxamine, and Cimetidine may increase the plasma concentration and overall exposure of Pentoxifylline and its active metabolites, primarily via inhibition of the CYP1A2 metabolic pathway.
Pharmacodynamic Interactions There is an additive risk of bleeding when Pentoxifylline is co-administered with Anticoagulants (like Warfarin) and Platelet Aggregation Inhibitors (like Aspirin or NSAIDs), requiring monitoring. Additionally, the drug may potentiate the effect of Antihypertensive Agents, potentially causing a small decrease in blood pressure.

Official Interaction Statements:

  • Co-administration with Theophylline has been documented to lead to elevated Theophylline plasma levels and associated toxicity risk.
  • The drug's exposure is increased in patients with renal impairment (Creatinine clearance below 30 ml/min) and hepatic impairment due to reduced clearance, as noted in the official prescribing information.

The regulatory profile defines the drug’s interaction structure through two main pathways: metabolic interference that results in increased systemic exposure of the drug, and potentiation of blood-related effects, specifically on blood clotting and blood pressure. These official statements delineate the combination restrictions and monitoring requirements.

Advertisements

Mechanism of Action

Pentoxifilina (Pentoxifylline) acts through multiple, interconnected pathways to modulate blood flow characteristics and immune signaling. Its mechanism centers on altering the biophysical properties of blood and influencing key inflammatory mediators.

Hemorheologic Modulation

This domain primarily addresses changes to the physical characteristics of blood components, specifically targeting red blood cell (erythrocyte) deformability and blood viscosity. As a methylxanthine derivative, Pentoxifilina acts to increase the flexibility of erythrocytes, promoting their transit through the microvasculature. This action decreases microcirculatory resistance, influencing local perfusion dynamics.

Cytokine and Phosphodiesterase Inhibition

Pentoxifilina modulates cellular signaling through the inhibition of phosphodiesterase (PDE) enzymes, resulting in elevated intracellular levels of cyclic adenosine monophosphate (cAMP). This rise in cAMP suppresses the nuclear translocation of NF-κB, a regulatory factor for inflammation. This cascade reduces the production of pro-inflammatory cytokines, such as Tumor Necrosis Factor-alpha ( TNF-alpha) and interleukins, decreasing the systemic concentration of these mediators.

Anti-Aggregation and Anti-Fibrinogenic Effects

This mechanism influences coagulation and tissue remodeling pathways. Pentoxifilina modifies blood component function by inhibiting platelet aggregation and reducing leukocyte adhesion to the vascular endothelium. Furthermore, it lowers the production of fibrinogenic molecules, modulating factors associated with vessel wall remodeling and fibrosis.

Advertisements

Dosage and Administration Information

How to Use Pentoxifilina Genfar

This section outlines the usage guidelines for pentoxifylline, the active component in Pentoxifilina Genfar. The information provided is descriptive of the medication's administration.


Administration Scope

The medication is supplied as an extended-release oral tablet and is administered by the oral route. The tablet must be swallowed whole and should not be crushed, split, or chewed to ensure the integrity of the controlled-release mechanism.


Dosing and Scheduling

The standard adult dosing regimen typically starts at 400 mg three times daily (TID). This dose is generally taken with food or after meals to enhance gastrointestinal tolerance. The maximum recommended daily intake is 1200 mg.

If a patient experiences intolerance to the higher dose, the schedule may be reduced to 400 mg twice daily (BID). Treatment is typically continued for a minimum of eight weeks before the therapeutic effect is formally assessed.


Population-Specific Adjustments

For patients with severe renal impairment (creatinine clearance less than 30 mL/min), the dosage is reduced to 400 mg once a day. In cases where a dose is missed, the standard approach is to skip the missed dose if it is almost time for the next scheduled dose, and not double the dose to compensate.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies

Research evidence on the compound has been evaluated in multiple studies, primarily for its use in managing symptoms of chronic occlusive peripheral arterial disease (PAD), specifically intermittent claudication. Studies examined the compound's effect on specific biological pathways related to blood flow.


Randomized Controlled Trials (RCTs)

The first line of evidence examined whether the compound was associated with managing intermittent claudication, the pain that occurs in leg muscles during exercise due to PAD. Multiple trials investigated whether the compound was related to walking distance outcomes.

  • Walking Outcomes: Low-certainty evidence suggests that the compound may be associated with an improvement in both the pain-free walking distance (PFWD) and the total walking distance (TWD) compared to a placebo. However, the evidence on its effect on the ankle-brachial pressure index (ABI) was found to be inconclusive in several studies.
  • Safety Profile: Studies have reported on the compound's safety profile. Common reported side effects include gastrointestinal symptoms such as nausea and abdominal discomfort. The compound was generally reported as well tolerated, though evidence certainty is low to moderate.
  • Comparative Research: Research has compared the compound's effects against other agents, but the available data are limited and have not allowed for meaningful, pooled conclusions in head-to-head comparisons.

Observational Studies and Emerging Research

Beyond PAD, the compound's anti-inflammatory and hemorheologic properties have been investigated in other areas:

  • Renal Health: Research has studied the compound's use in patients with diabetic kidney disease (DKD), exploring associations with a reduction in protein in the urine (albuminuria) and a potential delay in the loss of kidney function.
  • Other Conditions: Other studies have investigated the compound's potential role in conditions like chronic venous leg ulcers and as an adjunct treatment in specific psychiatric conditions, with ongoing research continuing to explore these areas.
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Pentoxifilina Genfar (FAQ)


Q: Does Pentoxifilina Genfar affect blood pressure?

Official safety information reports that the medication may affect blood pressure, listing both hypotension (low blood pressure) and hypertension (high blood pressure) as possible side effects. Due to these potential effects, official prescribing information advises caution for individuals who already have low or unstable blood pressure.


Q: Can Pentoxifilina Genfar interact with herbal supplements?

Regulatory sources caution about the potential for interaction with agents that affect blood clotting. This includes certain herbal products that are known to have blood-thinning properties. The combination may require careful monitoring by a healthcare professional, as it could increase the risk of bleeding.


Q: Are there any major food restrictions while using Pentoxifilina Genfar?

According to official product information, there are no specific major food restrictions that must be followed while using this medication. In fact, it is often recommended that the drug be taken with food or after meals to help minimize gastrointestinal discomfort.


Q: What happens if I accidentally miss taking a dose?

If a dose is missed, official instructions advise taking it as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped entirely. Official guidance states that a double dose should not be taken to make up for a missed one.


Q: Does the medicine come in an extended-release form?

Yes, Pentoxifilina Genfar is manufactured and presented specifically as an extended-release oral tablet. This extended-release design is intended to deliver the active substance, pentoxifylline, slowly and consistently into the bloodstream over time.


Q: What happens to the body if too much Pentoxifilina is taken?

Official regulatory warnings describe specific symptoms associated with an overdose that may include flushing, low blood pressure (hypotension), agitation, fever, drowsiness, and seizures. In cases of suspected overdose, official warnings advise seeking immediate medical attention.


Q: Is it safe for a person with heart disease to use Pentoxifilina Genfar?

Official documents specify that the medication is contraindicated (must not be used) in patients with severe cardiac arrhythmias or recent acute myocardial infarction (heart attack). Its use requires careful consideration by a healthcare provider, and it is contraindicated in specific severe cardiac conditions.


Q: How quickly should I expect to see any difference after starting Pentoxifilina Genfar?

The time required for a therapeutic effect is typically not immediate. Official prescribing information indicates that it may take several weeks before a patient experiences a noticeable difference related to the medication’s intended purpose.


Q: Can Pentoxifilina Genfar cause changes in sleep patterns?

Yes, official safety information lists potential effects on the nervous system that relate to sleep. Reported side effects include both drowsiness or sleepiness and instances of difficulty sleeping (insomnia).


Q: What is the expected long-term effect of using Pentoxifilina?

The medication is typically used to manage symptoms of a chronic (long-term) condition. Treatment is usually continued for a minimum period before the effects are assessed. The specific duration of therapy should be determined by a healthcare provider based on the medical problem being addressed.


Q: Can Pentoxifilina Genfar be stopped suddenly, or does it need to be tapered?

Official guidance advises that patients should not stop taking the medication on their own, even if they feel it is not working. The decision to discontinue or change treatment should be made in consultation with a healthcare professional.


Q: Is there any information about using Pentoxifilina Genfar during pregnancy or breastfeeding?

The FDA has assigned the medication to Pregnancy Category C, meaning that risk cannot be definitively ruled out. Additionally, official documents state that the drug and its breakdown products are known to pass into human breast milk.


Q: Are there studies about Pentoxifilina's effect on wound healing?

The compound's anti-inflammatory and blood-flow properties have led to research exploring its role in conditions related to poor circulation, such as chronic venous leg ulcers. However, this use is considered part of emerging research and is not the primary licensed indication.


Q: What should be done if an adverse reaction occurs?

For common side effects, a patient should discuss them with their healthcare provider. Official guidance for serious adverse reactions is to stop the medication and seek immediate medical help, particularly for signs of bleeding or a major allergic reaction.


Q: Can Pentoxifilina Genfar cause problems with thinking or concentration?

While generally rare, official safety documents list symptoms of certain serious adverse events, such as aseptic meningitis or hepatitis, which have been reported to include cognitive effects such as confusion or trouble thinking clearly.


Q: How is the benefit of Pentoxifilina Genfar typically measured in a patient?

The clinical benefit of the medication is usually assessed by evaluating the patient's symptoms related to their circulation problem. This assessment includes monitoring for an improvement in outcomes like the distance a person can walk without experiencing pain (intermittent claudication).


Q: What is the legal classification of Pentoxifilina in different countries?

In major regulatory territories, this medication is classified as a prescription-only drug, meaning it requires a licensed prescription for dispensing. It is not listed as a controlled substance by regulatory bodies.


Q: Is there a possibility of becoming dependent on Pentoxifilina Genfar?

Pentoxifilina is classified by regulatory bodies as not a controlled medication. This classification indicates that the drug does not have a recognized potential for abuse or dependency.


Q: Why is Pentoxifilina Genfar sometimes mentioned in the context of sickle cell disease?

The compound has been examined in other medical contexts because of its fundamental mechanism, which is its ability to increase the flexibility of red blood cells and reduce blood thickness. These properties have made it a subject of research in various blood-related conditions.


Q: Are there any known drug-drug interactions that are considered major?

Yes, official safety information lists a contraindication with the medication Riociguat. A contraindication means the two drugs should not be combined due to a potentially severe risk of dangerously low blood pressure (hypotension).


Q: Does alcohol interact with Pentoxifilina Genfar?

Official product information does not specify a known direct interaction with alcohol. Official guidance indicates that alcohol consumption may impact the underlying circulatory conditions the medication is intended to address.


Q: Does Pentoxifilina Genfar interact with any diabetes medications?

Official regulatory information indicates that the medication may interact with antidiabetic agents (medicines used to manage blood sugar). This combination may lead to adverse effects, and therefore, monitoring of the patient's condition may be indicated.

Advertisements

How should Pentoxifilina Genfar be stored and disposed of?

Pentoxifilina (Pentoxifylline) Extended-Release Tablets must be stored strictly according to regulatory standards to maintain stability.

Storage Requirements

Condition Requirement
Temperature Store at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F).
Protection Keep away from excessive heat, moisture, and direct light. Do not freeze.
Container Keep the medication in a tightly closed, light-resistant container.
Child Safety Keep the product out of the reach of children.

Disposal Instructions

Do not keep outdated medicine or medicine no longer needed. To discard the product, consult a pharmacist or your local waste disposal service for instructions on pharmaceutical waste handling. The medication should not be flushed down the toilet or poured down a drain unless a specific official take-back instruction applies.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Pentoxifilina Genfar found in:

A-Z Index: